Please Wait.....
Report
Central lab Services Clinical Trial Lab Services - Company Evaluation Report, 2024
Market Report I 2025-08-01 I 114 Pages I MarketsandMarkets
The Central Lab Services Companies Quadrant is a comprehensive industry analysis that provides valuable insights into the global market for Central Lab Services. This quadrant offers a detailed evaluation of key market players, technological advancements, product innovations, and industry trends. MarketsandMarkets 360 Quadrants evaluated over 108 companies, of which the Top 11 Central Lab Services Companies were categorized and recognized as quadrant leaders.
Central Lab Services provide standardized, high-quality laboratory testing for pharmaceutical and biotech companies conducting clinical trials across multiple locations. Instead of relying on various local labs with different standards and equipment, all patient samples from trial sites worldwide are shipped to a single, central laboratory. This facility offers a comprehensive menu of services, including safety testing, complex biomarker analysis, sample management, and harmonized data reporting. This centralized approach ensures consistency, accuracy, and data integrity, which are essential for evaluating a drug's safety and efficacy.
The market is driven by the increasing number, complexity, and globalization of clinical trials. As research focuses more on biologics, personalized medicine, and rare diseases, the need for specialized and esoteric testing grows. Pharmaceutical companies increasingly outsource these functions to central labs to leverage their expertise, advanced technology, and global logistics networks, thereby reducing fixed costs and streamlining trial management. The rigorous demand from regulatory bodies like the FDA and EMA for high-quality, standardized data to support drug approval applications makes central labs an indispensable partner in drug development.
However, the industry faces considerable challenges. Managing the complex global logistics of time- and temperature-sensitive biological samples is a major operational hurdle fraught with risk. Adhering to a patchwork of different international regulations regarding data privacy and sample shipment adds further complexity. The high cost of advanced testing, particularly for genomics and specialized biomarkers, can be substantial. Moreover, the market is highly competitive, putting pressure on pricing and forcing providers to continuously invest in new technologies to maintain a competitive edge.
The 360 Quadrant maps the Central Lab Services companies based on criteria such as revenue, geographic presence, growth strategies, investments, and sales strategies for the market presence of the Central Lab Services quadrant. The top criteria for product footprint evaluation included Phase (Phase I, Phase II, Phase III, Phase IV), Therapeutic Area(Oncology, Infectious Diseases, Neurology, Cardiology, Other Therapeutic Areas), Service Type (Safety Testing, Immunology, Genetic Testing, Coagulation Testing, Pathology Testing, Biomarkers, Companion Diagnostics, Other Tests), Modality (Small Molecules, Biologics (Monoclonal Antibodies, Vaccines, Other Therapeutic Products), Cell & Gene Therapy, Medical Devices & IVD Devices), End User (Pharmaceutical & Biopharmaceutical Companies, CROs, Medical Device Companies, Other End Users).
Key Players:
Major vendors in the Central Lab Services market are Thermo Fisher Scientific Inc. (US), IQVIA (US), and ICON plc (Ireland).
The key strategies major vendors implement in the Central Lab Services market are partnerships, collaborations, product launches, and product enhancements.
Thermo Fisher Scientific Inc.
Thermo Fisher Scientific is the undisputed world leader in serving science, offering an unparalleled portfolio of analytical instruments, laboratory equipment, and biopharma services. Through its industry-leading brands, the company provides foundational tools for research, diagnostics, and manufacturing. Strategically, Thermo Fisher acts as an end-to-end partner for the pharmaceutical industry, supporting customers from initial discovery to commercial production. By focusing on high-growth areas like cell and gene therapy, expanding its digital science platforms, and capitalizing on its vast global scale, the company maintains its dominant position in the life sciences ecosystem.
IQVIA
IQVIA is a global leader in using data and science to help healthcare clients find better solutions for patients. Formed from the merger of IMS Health and Quintiles, its unique strength lies in combining advanced data analytics with deep clinical research expertise. IQVIA's strategy is to power smarter, faster drug development by leveraging its vast healthcare data and AI-driven CORE platform. By providing data-rich insights for trial design, patient recruitment, and real-world evidence studies, the company solidifies its position as an indispensable partner for the global life sciences industry.
ICON plc
ICON plc is a global leader in the contract research organization (CRO) industry, providing comprehensive drug and device development services. Following its transformative acquisition of PRA Health Sciences, the company boasts immense scale and a fully integrated service offering for its pharma and biotech clients. Strategically, ICON focuses on delivering patient-centric and decentralized clinical trials, leveraging technology to improve access and efficiency. By combining its deep therapeutic expertise with a commitment to data-driven solutions and operational excellence, ICON maintains its position as a top-tier partner in advancing global healthcare innovation.
1 INTRODUCTION 11
1.1 MARKET DEFINITION 11
1.2 STAKEHOLDERS 11
2 EXECUTIVE SUMMARY 12
3 MARKET OVERVIEW 17
3.1 INTRODUCTION 17
3.2 MARKET DYNAMICS 17
3.2.1 DRIVERS 18
3.2.1.1 Increasing number of clinical trials 18
3.2.1.2 Rising investments in research & development 18
3.2.1.3 Growing prevalence of rare diseases 19
3.2.1.4 Favorable government initiatives 20
3.2.2 RESTRAINTS 20
3.2.2.1 High costs associated with clinical trials 20
3.2.2.2 Shortage of skilled professionals 21
3.2.3 OPPORTUNITIES 22
3.2.3.1 Emerging markets worldwide 22
3.2.3.2 Decentralized and virtual clinical trials 22
3.2.4 CHALLENGES 23
3.2.4.1 Regulatory complexities 23
3.2.4.2 Limited patient diversity 24
3.2.4.3 Cybersecurity and intellectual property concerns 24
3.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 25
3.4 VALUE CHAIN ANALYSIS 26
3.4.1 RESOURCE ACQUISITION AND PREPARATION 26
3.4.2 CLINICAL TRIAL EXECUTION 26
3.4.3 DATA REPORTING AND RESULT SUBMISSION 26
3.4.4 PROMOTION AND REGULATORY FILING 26
3.5 ECOSYSTEM ANALYSIS 27
3.6 TECHNOLOGY ANALYSIS 28
3.6.1 KEY TECHNOLOGIES 29
3.6.1.1 Enzyme-linked immunosorbent assay 29
3.6.2 ADJACENT TECHNOLOGIES 29
3.6.2.1 Next-generation sequencing 29
3.7 KEY CONFERENCES AND EVENTS, 2025-2026 30
?
3.8 PORTER'S FIVE FORCES ANALYSIS 31
3.8.1 THREAT OF NEW ENTRANTS 32
3.8.2 THREAT OF SUBSTITUTES 32
3.8.3 BARGAINING POWER OF SUPPLIERS 32
3.8.4 BARGAINING POWER OF BUYERS 32
3.8.5 INTENSITY OF COMPETITIVE RIVALRY 33
3.9 IMPACT OF AI/GENERATIVE AI ON CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET 33
3.9.1 INTRODUCTION 33
3.9.2 MARKET POTENTIAL OF CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES 33
3.9.3 AI USE CASES 34
3.9.4 FUTURE OF GENERATIVE AI IN CLINICAL TRIAL LAB ECOSYSTEM 35
4 COMPETITIVE LANDSCAPE 36
4.1 OVERVIEW 36
4.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 36
4.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET 36
4.3 REVENUE ANALYSIS, 2020?2024 38
4.4 MARKET SHARE ANALYSIS, 2024 39
4.5 COMPANY VALUATION AND FINANCIAL METRICS 41
4.6 BRAND/PRODUCT COMPARISON 42
4.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 43
4.7.1 STARS 43
4.7.2 EMERGING LEADERS 43
4.7.3 PERVASIVE PLAYERS 43
4.7.4 PARTICIPANTS 43
4.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 45
4.7.5.1 Company footprint 45
4.7.5.2 Region footprint 46
4.7.5.3 Product type footprint 47
4.7.5.4 Therapeutic area footprint 48
4.7.5.5 Phase footprint 49
4.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 50
4.8.1 PROGRESSIVE COMPANIES 50
4.8.2 RESPONSIVE COMPANIES 50
4.8.3 DYNAMIC COMPANIES 50
4.8.4 STARTING BLOCKS 50
4.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 52
4.8.5.1 Detailed list of key startups/SMEs 52
4.8.5.2 Competitive benchmarking of key startups/SMEs 53
?
4.9 COMPETITIVE SCENARIO 54
4.9.1 PRODUCT LAUNCHES 54
4.9.2 DEALS 55
4.9.3 EXPANSIONS 56
4.9.4 OTHER DEVELOPMENTS 56
5 COMPANY PROFILES 57
5.1 KEY PLAYERS 57
5.1.1 THERMO FISHER SCIENTIFIC INC. 57
5.1.1.1 Business overview 57
5.1.1.2 Products/Services offered 58
5.1.1.3 Recent developments 59
5.1.1.3.1 Product launches 59
5.1.1.3.2 Deals 59
5.1.1.3.3 Expansions 60
5.1.1.4 MnM view 60
5.1.1.4.1 Key strengths 60
5.1.1.4.2 Strategic choices 60
5.1.1.4.3 Weaknesses and competitive threats 60
5.1.2 IQVIA 61
5.1.2.1 Business overview 61
5.1.2.2 Products/Services offered 62
5.1.2.3 Recent developments 63
5.1.2.3.1 Product launches 63
5.1.2.3.2 Deals 64
5.1.2.4 MnM view 64
5.1.2.4.1 Right to win 64
5.1.2.4.2 Strategic choices 64
5.1.2.4.3 Weaknesses and competitive threats 64
5.1.3 ICON PLC 65
5.1.3.1 Business overview 65
5.1.3.2 Products/Services offered 66
5.1.3.3 Recent developments 66
5.1.3.3.1 Product launches 66
5.1.3.3.2 Deals 67
5.1.3.4 MnM view 67
5.1.3.4.1 Right to win 67
5.1.3.4.2 Strategic choices 67
5.1.3.4.3 Weaknesses and competitive threats 67
5.1.4 CHARLES RIVER LABORATORIES 68
5.1.4.1 Business overview 68
5.1.4.2 Products/Services offered 69
5.1.4.3 Recent developments 70
5.1.4.3.1 Deals 70
5.1.4.3.2 Expansions 71
5.1.4.4 MnM view 71
5.1.4.4.1 Right to win 71
5.1.4.4.2 Strategic choices 71
5.1.4.4.3 Weaknesses and competitive threats 71
5.1.5 LABCORP 72
5.1.5.1 Business overview 72
5.1.5.2 Products/Services offered 73
5.1.5.3 Recent developments 74
5.1.5.3.1 Product launches 74
5.1.5.3.2 Deals 74
5.1.5.3.3 Expansions 75
5.1.5.3.4 Other developments 75
5.1.5.4 MnM view 76
5.1.5.4.1 Key strengths 76
5.1.5.4.2 Strategic choices 76
5.1.5.4.3 Weaknesses and competitive threats 76
5.1.6 QUEST DIAGNOSTICS 77
5.1.6.1 Business overview 77
5.1.6.2 Products/Services offered 78
5.1.6.3 Recent developments 78
5.1.6.3.1 Deals 78
5.1.7 MEDPACE 80
5.1.7.1 Business overview 80
5.1.7.2 Products/Services offered 81
5.1.7.3 Recent developments 81
5.1.7.3.1 Expansions 81
5.1.8 FRONTAGE LABS 82
5.1.8.1 Business overview 82
5.1.8.2 Products/Services offered 84
5.1.9 SGS SOCIETE GENERALE DE SURVEILLANCE SA 85
5.1.9.1 Business overview 85
5.1.9.2 Products/Services offered 86
5.1.9.3 Recent developments 87
5.1.9.3.1 Deals 87
5.1.10 EUROFINS SCIENTIFIC 88
5.1.10.1 Business overview 88
5.1.10.2 Products/Services offered 89
5.1.10.3 Recent developments 90
5.1.10.3.1 Deals 90
5.1.11 REPROCELL INC. 91
5.1.11.1 Business overview 91
5.1.11.2 Products/Services offered 91
5.1.11.3 Recent developments 92
5.1.11.3.1 Deals 92
5.1.12 ACM GLOBAL LABORATORIES 93
5.1.12.1 Business overview 93
5.1.12.2 Products/Services offered 93
5.1.12.3 Recent developments 93
5.1.12.3.1 Deals 93
5.2 OTHER PLAYERS 94
5.2.1 WORLDWIDE CLINICAL TRIALS 94
5.2.2 VERSITI 95
5.2.3 CTI CLINICAL TRIAL & CONSULTING 96
5.2.4 CLARITY LABORATORIES, INC 97
5.2.5 NOVOTECH 98
5.2.6 ARUP LABORATORIES 99
5.2.7 PRECISION MEDICINE GROUP 100
5.2.8 BIOAGILYTIX LABS 101
5.2.9 CERBA HEALTHCARE 102
5.2.10 ALMAC GROUP 103
5.2.11 MLM MEDICAL LABS 104
5.2.12 SALVUS BIORESEARCH SOLUTIONS LLP 105
5.2.13 UNILABS 106
6 APPENDIX 107
6.1 RESEARCH METHODOLOGY 107
6.1.1 RESEARCH DATA 107
6.1.1.1 Secondary data 107
6.1.1.2 Primary data 108
6.1.2 RESEARCH ASSUMPTIONS 110
6.1.3 RESEARCH LIMITATIONS 110
6.1.4 RISK ASSESSMENT 111
6.2 COMPANY EVALUATION MATRIX: METHODOLOGY 111
6.3 AUTHOR DETAILS 114
TABLE 1 TRADITIONAL VS. VIRTUAL CLINICAL TRIALS 23
TABLE 2 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:
ROLE OF COMPANIES IN ECOSYSTEM 28
TABLE 3 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:
KEY CONFERENCES AND EVENTS, 2025?2026 30
TABLE 4 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:
PORTER'S FIVE FORCES ANALYSIS 31
TABLE 5 KEY COMPANIES IMPLEMENTING AI 35
TABLE 6 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CENTRAL
LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, 2022-2025 36
TABLE 7 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:
DEGREE OF COMPETITION 39
TABLE 8 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:
REGION FOOTPRINT 46
TABLE 9 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:
PRODUCT TYPE FOOTPRINT 47
TABLE 10 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:
THERAPEUTIC AREA FOOTPRINT 48
TABLE 11 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:
PHASE FOOTPRINT 49
TABLE 12 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:
DETAILED LIST OF KEY STARTUPS/SMES 52
TABLE 13 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 53
TABLE 14 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:
PRODUCT LAUNCHES, JANUARY 2022-JANUARY 2025 54
TABLE 15 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:
DEALS, JANUARY 2022-JANUARY 2025 55
TABLE 16 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:
EXPANSIONS, JANUARY 2022-JANUARY 2025 56
TABLE 17 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:
OTHER DEVELOPMENTS, JANUARY 2022-JANUARY 2025 56
TABLE 18 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 57
TABLE 19 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED 58
TABLE 20 THERMO FISHER SCIENTIFIC INC: PRODUCT LAUNCHES,
JANUARY 2022-JANUARY 2025 59
TABLE 21 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022-JANUARY 2025 59
TABLE 22 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022-JANUARY 2025 60
TABLE 23 IQVIA: COMPANY OVERVIEW 61
TABLE 24 IQVIA: PRODUCTS/SERVICES OFFERED 62
TABLE 25 IQVIA: PRODUCT LAUNCHES, JANUARY 2022-JANUARY 2025 63
TABLE 26 IQVIA: DEALS, JANUARY 2022-JANUARY 2025 64
TABLE 27 ICON PLC: COMPANY OVERVIEW 65
TABLE 28 ICON PLC: PRODUCTS/SERVICES OFFERED 66
TABLE 29 ICON PLC: PRODUCT LAUNCHES, JANUARY 2022-JANUARY 2025 66
TABLE 30 ICON PLC: DEALS, JANUARY 2022-JANUARY 2025 67
TABLE 31 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW 68
TABLE 32 CHARLES RIVER LABORATORIES: PRODUCTS/SERVICES OFFERED 69
TABLE 33 CHARLES RIVER LABORATORIES: DEALS, JANUARY 2022-JANUARY 2025 70
TABLE 34 CHARLES RIVER LABORATORIES: EXPANSIONS, JANUARY 2022-JANUARY 2025 71
TABLE 35 LABCORP: COMPANY OVERVIEW 72
TABLE 36 LABCORP: PRODUCTS/SERVICES OFFERED 73
TABLE 37 LABCORP: PRODUCTS LAUNCHES, JANUARY 2022-JANUARY 2025 74
TABLE 38 LABCORP: DEALS, JANUARY 2022-JANUARY 2025 74
TABLE 39 LABCORP: EXPANSIONS, JANUARY 2022-JANUARY 2025 75
TABLE 40 LABCORP: OTHER DEVELOPMENTS, JANUARY 2022-JANUARY 2025 75
TABLE 41 QUEST DIAGNOSTICS: COMPANY OVERVIEW 77
TABLE 42 QUEST DIAGNOSTICS: PRODUCTS/SERVICES OFFERED 78
TABLE 43 QUEST DIAGNOSTICS: DEALS, JANUARY 2022-JANUARY 2025 78
TABLE 44 MEDPACE: COMPANY OVERVIEW 80
TABLE 45 MEDPACE: PRODUCTS/SERVICES OFFERED 81
TABLE 46 MEDPACE: EXPANSIONS, JANUARY 2022-JANUARY 2025 81
TABLE 47 FRONTAGE LABS: COMPANY OVERVIEW 82
TABLE 48 FRONTAGE LABS: PRODUCTS/SERVICES OFFERED 84
TABLE 49 SGS SOCIETE GENERALE DE SURVEILLANCE SA: COMPANY OVERVIEW 85
TABLE 50 SGS SOCIETE GENERALE DE SURVEILLANCE SA: PRODUCTS/SERVICES OFFERED 86
TABLE 51 SGS SOCIETE GENERALE DE SURVEILLANCE SA: DEALS,
JANUARY 2022-JANUARY 2025 87
TABLE 52 EUROFINS SCIENTIFIC: COMPANY OVERVIEW 88
TABLE 53 EUROFINS SCIENTIFIC: PRODUCTS/SERVICES OFFERED 89
TABLE 54 EUROFINS SCIENTIFIC: DEALS, JANUARY 2022-JANUARY 2025 90
TABLE 55 REPROCELL INC.: COMPANY OVERVIEW 91
TABLE 56 REPROCELL INC.: PRODUCTS/SERVICES OFFERED 91
TABLE 57 REPROCELL INC.: DEALS, JANUARY 2022-JANUARY 2025 92
TABLE 58 ACM GLOBAL LABORATORIES: COMPANY OVERVIEW 93
TABLE 59 ACM GLOBAL LABORATORIES: PRODUCTS/SERVICES OFFERED 93
TABLE 60 ACM GLOBAL LABORATORIES: DEALS, JANUARY 2022-JANUARY 2025 93
TABLE 61 WORLDWIDE CLINICAL TRIALS: COMPANY OVERVIEW 94
TABLE 62 VERSITI: COMPANY OVERVIEW 95
TABLE 63 CTI CLINICAL TRIAL & CONSULTING: COMPANY OVERVIEW 96
TABLE 64 CLARITY LABORATORIES, INC: COMPANY OVERVIEW 97
TABLE 65 NOVOTECH: COMPANY OVERVIEW 98
TABLE 66 ARUP LABORATORIES: COMPANY OVERVIEW 99
TABLE 67 PRECISION MEDICINE GROUP: COMPANY OVERVIEW 100
TABLE 68 BIOAGILYTIX LABS: COMPANY OVERVIEW 101
TABLE 69 CERBA HEALTHCARE: COMPANY OVERVIEW 102
TABLE 70 ALMAC GROUP: COMPANY OVERVIEW 103
TABLE 71 MLM MEDICAL LABS: COMPANY OVERVIEW 104
TABLE 72 SALVUS BIORESEARCH SOLUTIONS LLP: COMPANY OVERVIEW 105
TABLE 73 UNILABS: COMPANY OVERVIEW 106
TABLE 74 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:
RISK ASSESSMENT 111
FIGURE 1 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY PHASE, 2025 VS. 2030 (USD MILLION) 12
FIGURE 2 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY SERVICE TYPE, 2025 VS. 2030 (USD MILLION) 13
FIGURE 3 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY THERAPEUTIC AREA, 2025 VS. 2030 (USD MILLION) 14
FIGURE 4 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY MODALITY, 2025 VS. 2030 (USD MILLION) 14
FIGURE 5 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY END USER, 2025 VS. 2030 (USD MILLION) 15
FIGURE 6 GEOGRAPHICAL SNAPSHOT OF CENTRAL LAB SERVICES/CLINICAL
TRIAL LAB SERVICES MARKET 16
FIGURE 7 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:
DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 17
FIGURE 8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 25
FIGURE 9 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:
VALUE CHAIN ANALYSIS 27
FIGURE 10 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:
ECOSYSTEM ANALYSIS 28
FIGURE 11 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:
PORTER'S FIVE FORCES ANALYSIS 31
FIGURE 12 AI USE CASES 34
FIGURE 13 REVENUE ANALYSIS OF KEY PLAYERS, 2020?2024 (USD MILLION) 38
FIGURE 14 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024 39
FIGURE 15 RANKING OF KEY PLAYERS IN CENTRAL LAB SERVICES/CLINICAL
TRIAL LAB SERVICES MARKET, 2024 40
FIGURE 16 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF
KEY VENDORS, 2025 41
FIGURE 17 FINANCIAL METRICS, 2025 41
FIGURE 18 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: BRAND/PRODUCT COMPARISON 42
FIGURE 19 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:
COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 44
FIGURE 20 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:
COMPANY FOOTPRINT 45
FIGURE 21 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:
COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 51
FIGURE 22 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024) 58
FIGURE 23 IQVIA: COMPANY SNAPSHOT (2024) 62
FIGURE 24 ICON PLC: COMPANY SNAPSHOT (2023) 65
FIGURE 25 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2023) 69
FIGURE 26 LABCORP: COMPANY SNAPSHOT (2024) 73
FIGURE 27 QUEST DIAGNOSTICS: COMPANY SNAPSHOT (2024) 77
FIGURE 28 MEDPACE: COMPANY SNAPSHOT (2024) 80
FIGURE 29 FRONTAGE LABS: COMPANY SNAPSHOT (2023) 83
FIGURE 30 SGS SOCIETE GENERALE DE SURVEILLANCE SA: COMPANY SNAPSHOT (2024) 86
FIGURE 31 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2024) 89
FIGURE 32 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:
RESEARCH DESIGN 107
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security